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HGE presents clinically as an acute febrile illness, although
the nonspecific symptoms of infection, most commonly fever,
headache, and myalgia, make the diagnosis problematic. Likewise, HGE-associated laboratory findings, including leukopenia, thrombocytopenia, and elevated liver enzymes, are relatively nonspecific. A history of tick bite or tick exposure, while
suggestive, is not diagnostic. Although several recent reports
have described successful cultivation of the HGE agent (26,
29), the procedure is lengthy and the sensitivity has not been
determined. Serologic tests, particularly indirect immunofluorescence antibody (IFA) assays, are commonly used but are
often negative during the acute phase of infection. The recognition of cytoplasmic inclusions, or morulae, in infected cells
during the examination of blood smears can be diagnostic;
however, morulae have not been observed in numerous cases
subsequently confirmed by other criteria (1, 5). PCR assays
have been used often, mostly in research-oriented settings, and
have the advantage of being able to yield positive results during
the early acute phase of illness. PCR-based assays have proven
critical for the identification and subsequent characterization
of the ehrlichiae and have been developed for use with various
clinical samples, but whole blood is the most commonly used
source (2, 9, 12, 30). A PCR assay has been shown to be
sensitive for identifying E. chaffeensis in acute-phase human
blood samples (2, 24), and a nested PCR assay was used in the
initial study that identified an Ehrlichia species as being the
etiologic agent of HGE (13). More recent HGE studies have
mainly used the primer set originally described by Chen et al.
(13) for identification of the agent (23). To date, several alternative PCR assays have been described (6, 35), but these assays
have not been thoroughly tested on human and veterinary
specimens. The goal of this study was to develop a sensitive
and specific PCR assay for the diagnosis of HGE and for the
identification of GE in potential vector and host species.

The ehrlichiae are obligately intracellular bacteria and have
been characterized as pathogens of medical and veterinary
importance. Two forms of human ehrlichiosis have been reported in the United States: human monocytic ehrlichiosis
(HME) and human granulocytic ehrlichiosis (HGE). The first
cases of HME were described in 1987 (32), and the etiologic
agent was subsequently identified as Ehrlichia chaffeensis (2,
15). HGE was first described in 1994 and differs from HME in
that granulocytic leukocytes serve as the primary target cells
(13). The Ehrlichia species responsible for HGE has not been
defined, although the nucleotide sequence of the 16S rRNA
gene (16S rDNA) of the HGE agent suggests a close relationship to Ehrlichia equi, the agent of equine granulocytic ehrlichiosis, and Ehrlichia phagocytophila, which is responsible for
infections of ruminants in Europe (13). Studies supporting the
close relationship of the HGE agent to E. equi and E. phagocytophila have included descriptions of the serologic crossreactivity of these organisms (3, 19) and a report that a horse
experimentally infected with the HGE agent was resistant to an
E. equi challenge (7).
The initial reports of HGE were in Minnesota and Wisconsin, but recent studies have shown that the disease also occurs
in the northeastern United States and northern California (3,
11, 13, 21, 25, 28, 42). Human infections with a granulocytic
Ehrlichia species have also been described in Europe (4, 10, 22,
36, 38). The HGE agent has been associated with the deer tick,
Ixodes scapularis (3, 34, 35), which might serve as the primary
vector. Additional vectors, and a mammalian reservoir, have
not been determined, although dogs living in areas where HGE
is endemic can be naturally infected with granulocytic ehrlichiae (GE) (27, 31, 37). Rodents, particularly white-footed
mice (Peromyscus leucopus), are competent experimental hosts
and may serve as a natural reservoir (39, 40, 42).

MATERIALS AND METHODS

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, 1600 Clifton Rd., MS G-13, Atlanta, GA 30333.
Phone: (404) 639-1075. Fax: (404) 639-4436. E-mail: rfm2@cdc.gov.

Samples. EDTA–whole-blood and serum samples were collected in June 1995
from seven human patients with suspected ehrlichiosis in Westchester County,
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A sensitive and specific nested PCR assay was developed for the detection of granulocytic ehrlichiae. The
assay amplifies the 16S rRNA gene and was used to examine acute-phase EDTA-blood and serum samples
obtained from seven humans with clinical presentations compatible with human granulocytic ehrlichiosis. Five
of the seven suspected cases were positive by the PCR assay using DNA extracted from whole blood as the
template, compared with a serologic assay that identified only one positive sample. The PCR assay using DNA
extracted from the corresponding serum samples as the template identified three positive samples. The
sensitivity of the assay on human samples was examined, and the limit of detection was shown to be fewer than
2 copies of the 16S rRNA gene. The application of the assay to nonhuman samples demonstrated products
amplified from template DNA extracted from Ixodes scapularis ticks collected in Rhode Island and from
EDTA-blood specimens obtained from white-tailed deer in Maryland. All PCR products were sequenced and
identified as specific to granulocytic ehrlichiae. A putative variant granulocytic ehrlichia 16S rRNA gene
sequence was detected among products amplified from both the ticks and the deer blood specimens.
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FIG. 1. Schematic representation of the GE 16S rDNA, showing the relative
locations of PCR primers used for the primary (ge3a and ge10r) and nested (ge9f
and ge2) amplification reactions. The orientation of each primer is indicated by
an arrowhead, and the sizes of the primary and nested products are shown. Scale,
16S rDNA base numbering. Small rectangle, region where sequence differences
between the HGE agent, E. equi, and the GE variant were noted.

DNA sequencing and data analysis. DNA sequencing reactions used fluorescence-labeled dideoxynucleotide technology (Dye Terminator Cycle Sequencing
Ready Reaction Kit; Perkin-Elmer, Applied Biosystems Division). Sequencing
reaction products were separated, and data were collected with an ABI 377
automated DNA sequencer (Perkin-Elmer, Applied Biosystems Division). Sequences were edited and assembled with the Staden software programs (17) and
were analyzed with the Wisconsin Sequence Analysis Package (Genetics Computer Group, Madison, Wis.) (18). The 16S rDNA sequences used for comparison were obtained from the GenBank database and included the HGE agent
(accession no. U02521), E. equi (M73223), and E. phagocytophila (M73220).

RESULTS
Nested PCR assay design and use with human whole blood.
The initial testing of PCR assays used numerous primers and
primer combinations and included both direct and nested PCR
protocols (data not shown). A nested assay using primers ge3a
and ge10r in the primary reaction, followed by ge9f and ge2 in
a nested reaction, appeared to provide excellent sensitivity.
The locations of these primers within the 16S rRNA gene of
the HGE agent are illustrated in Fig. 1. Primers ge9f and ge10r
were previously described by Chen et al. (13). Samples were
collected from seven humans in Westchester County, N.Y., an
area within the geographic range of I. scapularis ticks. These
patients were suspected of having HGE on the basis of clinical
presentation, and both EDTA–whole-blood and serum samples from the acute phase were available. Results of the nested
assay using template DNA extracted from EDTA–whole-blood
specimens are shown in Fig. 2. Samples 1, 2, and 4 were
positive in the primary amplification (Fig. 2A, lanes 1, 2, and
4), as indicated by the 932-bp product. Two of the three positives showed low levels of product (Fig. 2A, lanes 1 and 2).
Sample 4 (Fig. 2A, lane 4) showed an amount of product fairly
comparable to that of the positive control. The results of the
nested PCR assay (Fig. 2B) demonstrated that samples 1, 2, 4,
5, and 6 (lanes 1, 2, 4, 5, and 6) were positive, as indicated by
the 546-bp product. Products from each of the five positive
samples show bands clearly evident on the ethidium bromidestained agarose gel, and the intensity of each band is comparable to that of the positive control. Duplicate aliquots of each
human blood sample were independently extracted and PCR
amplified, and these produced results identical to those shown
in Fig. 2 (data not shown).
PCR assay using human serum. PCR was performed on
DNA extracted from serum samples obtained from the same
seven patients whose whole-blood specimens were tested by
PCR as described above. The products of the amplifications on
the serum-derived templates are shown in Fig. 3. Whereas the
primary amplification produced no detectable products for any
of the serum samples (Fig. 3A, lanes 1 to 7), the nested PCR
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N.Y. I. scapularis ticks were collected from Trustom Pond, R.I. Blood specimens
from white-tailed deer were collected from Prince Georges County, Md. Human
blood samples were stored at 4°C prior to DNA extraction. DNA was extracted
from each sample within 4 weeks of the date the blood samples were drawn.
White-tailed deer blood samples and ticks were stored at 220°C prior to DNA
extraction.
Controls. A PCR-amplified region of the 16S rDNA was cloned and used as a
positive control for subsequent amplifications. The cloned fragment was amplified from DNA extracted from the blood of one of the PCR-positive patients
from Westchester County, N.Y., by using primers ec12 and ec9 as previously
described (2). The amplified product was purified by using the manufacturer’s
recommended protocol with the Wizard PCR Preps DNA Purification System
(Promega Corporation, Madison, Wis.). The purified product was ligated into
plasmid vector pGEM-T, by using the pGEM-T Vector System kit (Promega).
The ligation product was transformed into Escherichia coli XL1-Blue (Stratagene, La Jolla, Calif.) by electroporation, and individual white colonies were
selected after growth on Luria-Bertani agarose with ampicillin (50 mg/ml). Plasmid DNA was purified from overnight cultures by using the Qiagen (Chatsworth,
Calif.) Plasmid Kit, and the insertion was confirmed as the HGE agent 16S
rRNA gene by DNA sequencing. This construct, named pFC4, was used as a
positive control where indicated in the text.
Serologic testing. An IFA assay was used to screen human sera for anti-HGE
agent antibodies by using E. equi antigen slides as a surrogate antigen (Fuller
Laboratories, Fullerton, Calif.). Sera were initially screened at dilutions of 1:64
and 1:128. Fluorescein isothiocyanate (FITC)-conjugated goat anti-human immunoglobulin G (IgG) (heavy and light chain; Kirkegaard & Perry Laboratories,
Gaithersburg, Md.) was used to identify antibodies reactive to E. equi-infected
horse neutrophils. Positive- and negative-control sera were included in each
assay. Titers of positive serum samples were subsequently determined to end
point. The IgM-specific IFA assay utilized FITC-conjugated goat anti-human
IgM (Kirkegaard & Perry Laboratories). Sera for the IgM assay were first
depleted of IgG by use of a protein G affinity method (Quik-Sep IgM; Isolab,
Akron, Ohio).
DNA purification. Total DNA was purified from 200 ml of EDTA-whole blood
(from humans or white-tailed deer) with the QIAamp blood kit (Qiagen). The
protocol used was that suggested by the manufacturer. Briefly, detergent lysis was
carried out in the presence of proteinase K for 10 min at 70°C. The lysed material
was applied to a spin column containing a silica gel-based membrane and was
washed twice. Purified DNA was eluted from the columns in 200 ml of Tris (10
mM; pH 8.0) and was stored at 4°C until it was used as the template for PCR
amplification.
DNA was purified from serum samples by using the QIAamp blood kit essentially as described above. The only modification from the EDTA-blood protocol
was an initial concentration step that involved the centrifugation of approximately 1 ml of each serum sample for 2 min at 12,000 3 g. The supernatant was
removed except for approximately 200 ml that was used to resuspend the serum
sediment. The resuspended material was then used for DNA extraction.
DNA was purified from adult I. scapularis ticks by using a modification of the
QIAamp tissue kit protocol (Qiagen). Individual ticks were placed in 1.5-ml
microcentrifuge tubes containing 50 ml of phosphate-buffered saline (10 mM; pH
7.4) and were crushed with a disposable micropestle (Kontes Scientific Glassware/Instruments, Vineland, N.J.). After the addition of 150 ml of phosphatebuffered saline (10 mM; pH 7.4), the QIAamp tissue extraction protocol was
followed as described by the manufacturer (Qiagen).
PCR amplification. PCR amplifications were performed in a Perkin-Elmer
9600 thermal cycler, and reagents were from the GeneAmp PCR Kit with
AmpliTaq DNA polymerase (Perkin-Elmer, Applied Biosystems Division, Foster City, Calif.). Primary reactions used 5 ml of purified DNA as the template in
a total volume of 50 ml. Amplifications contained 200 mM each deoxynucleoside
triphosphate (dATP, dCTP, dGTP, and dTTP), 1.25 U of Taq polymerase, and
0.5 mM each primer. Primers were ge3a (59 CACATGCAAGTCGAACGGAT
TATTC) and ge10r (59 TTCCGTTAAGAAGGATCTAATCTCC). Cycling conditions involved an initial 2-min denaturation at 95°C, followed by 40 cycles, each
consisting of a 30-s denaturation at 94°C, a 30-s annealing at 55°C, and a 1-min
extension at 72°C. These 40 cycles were followed by a 5-min extension at 72°C.
Reaction products were subsequently maintained at 4°C until they were analyzed
by agarose gel electrophoresis or used as templates for nested reactions.
Nested amplifications used 1 ml of the primary PCR product as the template
in a total volume of 50 ml. Each nested amplification contained 200 mM each
deoxynucleoside triphosphate (dATP, dCTP, dGTP, and dTTP), 1.25 U of Taq
polymerase, and 0.2 mM each primer: ge9f (59 AACGGATTATTCTTTATAG
CTTGCT) and ge2 (59 GGCAGTATTAAAAGCAGCTCCAGG). Nested cycling conditions were as described for the primary amplification, except that 30
cycles were used. Reaction products were subsequently maintained at 4°C until
they were analyzed by agarose gel electrophoresis or purified for DNA sequencing.
Quality control included both positive and negative controls that were extracted and PCR amplified in parallel with all specimens. Human whole-blood
DNA extractions and PCR amplifications were done in duplicate. In order to
minimize the potential for contamination, DNA extractions, PCR setup, and
agarose gel electrophoresis were performed in three separate rooms.
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assays showed products of the appropriate size for samples 2,
4, and 5 (Fig. 3B, lanes 2, 4, and 5).
Serologic testing of human samples. The serum samples
from the seven human patients were tested for antibodies by
IFA assay, and six of the seven were negative (IFA titer, ,64).
The only IFA-positive serum was from patient 1, with a reciprocal titer of 512. Furthermore, an isotype-specific IFA assay
showed that the response of this patient was restricted to the
IgM class, indicative of an acute infection. The results of the
PCR and IFA assays for the human blood and serum samples
are summarized in Table 1.
PCR detection of ehrlichial DNA in ticks. Application of the
assay to potential vector species was tested with DNA extracted from 31 flat, unengorged female I. scapularis ticks and
30 flat, unengorged female Dermacentor variabilis ticks collected from Trustom Pond, R.I. Whereas none of the amplifications using the DNA extracted from D. variabilis ticks
showed any products (data not shown), five of the Ixodes extracts (16%) showed products of the correct size. Figure 4A
shows the results of the nested amplification using template
DNA extracted from 13 of the I. scapularis ticks and includes
the five positive products (lanes 1, 4, 6, 7, and 12). All the tick
extracts were negative when tested by PCR assay for E. chaffeensis (data not shown).
PCR of ehrlichial DNA from white-tailed deer. DNA was
also extracted from EDTA–whole-blood samples obtained from
white-tailed deer in Prince Georges County, Md. Thirty-two
deer blood samples were tested with the HGE-specific nested
PCR assay, and products of the correct size were amplified from
three of these (9.4%). Figure 4B shows the nested PCR products for 13 of the deer templates, including the three positives
(lanes 4, 7, and 12). All the deer blood extracts were negative
when tested by PCR assay for E. chaffeensis (data not shown).

FIG. 3. PCR products amplified from DNA purified from human serum
samples (lanes 1 to 7) and from positive (1) and negative (2) controls. (A)
Primary amplification products. The expected size (932 bp) is indicated. (B)
Nested amplification products. The expected size (546 bp) is noted. Lanes M are
size standards and show the HaeIII digest of phage fX174 DNA.

Sensitivity of the nested PCR assay. The sensitivity of the
assay was assessed by a spiking experiment that involved the
addition of a known quantity of a plasmid (pFC4) containing
the HGE 16S rRNA gene sequence to DNA extracted from
ehrlichia PCR-negative human EDTA-blood samples. Each
primary reaction mixture contained the same amount of background human genome DNA (5 ml) and 1 ml from a series of
10-fold serial dilutions of pFC4. The nested reactions were
performed as described in Materials and Methods and used
1 ml of the primary reaction product as the template. By using
this approach, 10-fold serial dilutions of the purified, quantitated plasmid DNA were tested, and the nested PCR amplification products are shown in Fig. 5. The limit of detection was
determined to be approximately 1.93 copies (Fig. 5, lane 8).
These data were reproduced by using three different serial
dilutions of pFC4 and by using the DNA purified from three

TABLE 1. Results of serologic and PCR assays for acute-phase
samples collected from suspected HGE patients
residing in Westchester County, N.Y.
PCR result for:

Patient

Serologic assaya
result

EDTA-blood

Serum

1
2
3
4
5
6
7

1
2
2
2
2
2
2

1
1
2
1
1
1
2

2
1
2
1
1
2
2

a
IFA assay using E. equi antigen slides and FITC-conjugated goat anti-human
IgG (heavy and light chain).
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FIG. 2. PCR products amplified from DNA purified from human EDTAblood samples (lanes 1 to 7) and from positive (1) and negative (2) controls. (A)
Primary amplification products. The expected size (932 bp) is indicated. (B)
Nested amplification products. The expected size (546 bp) is noted. Lanes M are
size standards and show the HaeIII digest of phage fX174 DNA.

J. CLIN. MICROBIOL.
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different noninfected humans as a nonspecific competitor
(data not shown).
Specificity of the nested PCR assay. Positive and negative
controls were included with each PCR amplification to ensure
the specificity of the assay. Negative controls consisted of human EDTA-blood or serum samples collected from noninfected individuals and were extracted in parallel with the test
samples. No products were amplified from any of the negativecontrol samples (Fig. 2 to 4). All PCR amplifications were
repeated in order to confirm the initial results and assess the
reproducibility of the assay; the results of the repeat amplifications were identical to the results shown in Fig. 2 to 4 (data
not shown). The specificity of the assay was further assessed by
attempting to amplify products from non-GE bacteria by using
DNA templates purified from infected human EDTA-blood
samples or tissue culture-grown bacteria. No products were
amplified from other Ehrlichia species that were tested, including E. chaffeensis, E. canis, E. sennetsu, and E. risticii. Also
negative were DNAs from the phylogenetically related bacteria
Bartonella henselae and Rickettsia rickettsii and from purified
DNA products containing Rhizobium sp., Agrobacterium sp.,
and Mycoplana sp. (data not shown).
DNA sequencing. The nested PCR assays amplified a 546-bp
portion of the GE 16S rRNA gene (Fig. 1). Each PCR product
was sequenced, and the sequences determined for the products
from the human blood and serum samples, and from three of
the five positive ticks, were identical to each other and to the
16S rRNA gene sequence of the HGE agent previously described by Chen et al. (13). Two of the tick-derived products
and all three of the deer PCR products showed sequences that
differed from the 16S rDNA sequence of the HGE agent by 2
bases and from the corresponding E. equi sequence by 1 nucleotide. The region near the 59 end of the 16S rRNA gene is
where the GE variant differs from the HGE agent and E. equi.
This region of variation is indicated in Fig. 1, and the nucleotides that differ are shown in Fig. 6.

1093

FIG. 5. Sensitivity testing of the GE PCR assays. (A) Products of the primary
assay using 10-fold serial dilutions of the positive control (pFC4) as templates.
Lanes 1 through 10 correspond to template copy numbers ranging from 1.93 3
107 (lane 1) to 0.0193 (lane 10). The expected size of the primary product (932
bp) is indicated. (B) Products of nested PCR using 1 ml of the corresponding
primary product as the template, with the expected size of the nested PCR
product (546 bp) indicated. Lanes M are molecular weight standards and show
the HaeIII digest of phage fX174 DNA. Lanes C, negative controls representing
the background human genome DNA as the template without the addition of the
plasmid-cloned ehrlichia 16S rDNA.

DISCUSSION
HGE produces a wide range of clinical manifestations, from
a relatively benign febrile illness to severe and sometimes fatal
infections. Tetracycline and doxycycline have been reported to
be therapeutically efficacious, and patients generally respond
within 48 h of treatment (20). If administered promptly, these
antibiotics can effectively prevent severe forms of the illness.
Therefore, the prompt diagnosis and treatment of HGE is
imperative. Diagnosis of HGE has been based primarily on
IFA and PCR-based assays. The nested PCR assay described
in this report is both sensitive and specific. The assay confirmed
infection with the HGE agent in five of the seven human
samples examined. Of these five PCR-positive cases, only one
was positive by serologic (IFA) assay, and an isotype-specific
IFA assay showed that the response was restricted to the IgM

FIG. 6. GE sequence differences. The region of the 16S rRNA gene where
sequence differences were noted is shown for the HGE agent, E. equi, and a
novel GE variant. The differing nucleotides are boxed, and the numbers above
these are the corresponding base number designations for the HGE agent 16S
rDNA sequence reported by Chen et al. (13) (GenBank accession no. U02521).
The E. equi sequence was obtained from GenBank (accession no. M73223).
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FIG. 4. Nested PCR products amplified from DNA purified from I. scapularis ticks (A) and white-tailed deer (B). Positive (1) and negative (2) controls
are shown, and the expected size of the nested products (546 bp) is indicated.
Lanes M are size standards and show the HaeIII digest of phage fX174 DNA.
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cently, it was reported that 50% of I. scapularis ticks collected
in Connecticut were PCR positive, although it was not indicated if these positives were confirmed by DNA sequencing,
and geographic variations in prevalence were noted (34). The
evidence accumulated to date suggests that, like that of other
tick-transmitted pathogens, the prevalence of GE in tick populations may vary significantly based on location and seasonal
parameters.
The specificity of the assay was examined, and the assay will
not amplify products from DNA purified from the other Ehrlichia species that have been tested or from B. henselae or
R. rickettsii. The assay will amplify the 16S rDNA of a whitetailed deer agent determined to be an Ehrlichia species that
was recently described from Georgia and Oklahoma (reference
14 and data not shown). Although the white-tailed deer agent
was not observed in the current study involving deer from
Maryland, positive PCR products from deer-derived templates
need to be further analyzed by DNA sequencing, particularly
because there may be some overlap in the geographic distribution of these agents.
The specificity of the assay was also assessed by sequencing
the PCR amplicons. The DNA sequence determined for each
of these products was strongly homologous ($99.4% identity
in 497 bp) to previously reported 16S rDNA sequences of GE.
The sequences for the products amplified from each of the
human blood and serum samples were identical to the published nucleotide sequence of the HGE agent (13). In addition
to the samples described in this report, the nested assay has
been used by the CDC Rickettsial Laboratory to test more
than 500 human samples (EDTA-blood, citrated blood, and
serum), and the only products ever amplified (20 total positives, including the 5 in this study) were identical in sequence
to the HGE agent 16S rDNA. The sequences for three of the
tick-derived amplicons were also identical to each other and to
the HGE agent sequence. These data support the correspondence between HGE and I. scapularis as a potential vector of
the disease, as previously suggested (35, 39). However, the 16S
rRNA gene sequences determined for the PCR products from
two of the ticks, and from all three positive white-tailed deer,
showed a variant GE sequence that differs from the HGE
agent sequence by 2 bases. The sequence of the GE variant we
found in Maryland white-tailed deer and Rhode Island ticks
was identical to the sequence recently described for an Ehrlichia species from white-tailed deer in Wisconsin (8). The identification of this variant in three diverse locations, and in populations of both white-tailed deer and ticks, suggests that it
may be relatively widespread and constant in nature. Whether
the GE variant identified in this report causes human or veterinary disease remains to be determined. An isolate of this
variant would be valuable and would allow experimental infection studies to address this issue.
A recent report described the PCR amplification of an ehrlichia 16S rDNA sequence from white-footed mice in Minnesota (40). The only difference between this sequence and the
16S rDNA sequence of the HGE agent (GenBank accession
no. U02521) is a single deletion of a thymidine residue at position 153 of the HGE agent. This thymidine residue is present
in the GE variant described in the present study. It remains to
be determined whether the GE variant reported here (found in
ticks and deer), the HGE agent, the agent found in Minnesota
white-footed mice, E. equi, and E. phagocytophila represent
natural variants of a single species. Certainly, the 16S rDNA
sequences that have been amplified and sequenced for these
organisms are very well conserved, with 1 to 3 nucleotide differences. The identification and DNA sequencing of genetic
elements that are more variable than the 16S rDNA will be
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class (titer, 1:512). Follow-up studies by IFA assay on convalescent-phase samples showed that two patients who were PCR
positive and IFA negative in this study subsequently seroconverted (41). Convalescent-phase samples were not available for
the other two PCR-confirmed cases. These data suggest that
PCR-based assays represent a preferable method for evaluating suspected HGE cases during the acute phase of infection.
Additionally, some sera from confirmed HGE cases are crossreactive with antigens of the agent of HME, E. chaffeensis,
when assayed by IFA assay (16, 33). PCR-based assays are
capable of discriminating between these two closely related
organisms that produce infections with very similar clinical
presentations.
The nested PCR assay was tested with template DNA purified from human serum samples and resulted in positive results
for samples collected from three of the five patients whose
whole-blood specimens were positive by PCR. These results
support the studies of Pancholi et al. (35) and of Dumler and
Bakken (21) by demonstrating that PCR amplification of the
HGE agent DNA from human serum is feasible, although not
as sensitive as PCR using EDTA-blood. However, PCR represents a valuable adjunct to serologic testing when only an
acute-phase serum sample is available, and it will facilitate the
confirmation of cases that would otherwise be missed.
The nested assay as described, from DNA extraction through
agarose gel electrophoretic analysis, can be completed by an
experienced laboratorian within an 8-h workday. A simple,
commercially available kit was used for DNA extraction, further simplifying the procedure and making it more amenable
to routine use in diagnostic laboratories. Modifications of the
assay using colorimetric, fluorescent, and luminescent detection are currently being evaluated and have the potential to
further enhance the applicability of the assay. The assay can be
used for the routine diagnosis of HGE in human clinical samples and is being used in this manner in the Centers for Disease
Control and Prevention (CDC) Rickettsial Laboratory, but it
was designed primarily as a research tool to provide optimal
sensitivity and specificity with a variety of samples. The sensitivity of the assay requires the use of positive and negative
controls for both DNA extraction and PCR amplification, and
laboratorians must be trained in proper PCR techniques in
order to avoid contamination.
The sensitivity of the PCR amplification was assessed by
using a plasmid control and was shown to be fewer than 2
copies of the 16S rRNA gene. Infected granulocytes appear to
contain many bacteria when examined by light or electron
microscopy, and ehrlichia DNA can often be detected by lesssensitive PCR assays. However, for samples where few bacteria
are present, the sensitivity provided by this assay should prove
useful. As evidence, single-step PCR assays were negative for
each of the seven human serum samples tested in this report,
while the nested assay produced positive results from three of
these samples. In our laboratory, the assay has not produced
equivocal plus/minus results; all positives have been distinguished by products easily visible on ethidium bromide-stained
agarose gels. In addition to the HGE cases described in this
study, the assay has been used to identify GE DNA and confirm infections in 4 cases when only acute-phase EDTA-blood
samples were available and 11 cases when only acute-phase
serum samples were available.
The ability of the assay to detect ehrlichia DNA in veterinary
samples was demonstrated. The amplification of DNA from
I. scapularis ticks collected from Trustom Pond, R.I., showed
that 16% (5 of 31) were PCR positive for GE. PCR of DNA
from deer blood specimens collected in Prince Georges
County, Md., showed that 9.4% (3 of 32) were positive. Re-
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instrumental in resolving the phylogenetic relationship between the HGE agent and the increasing number of GE variants that are being found in nature.
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